Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
166M
-
Number of holders
-
133
-
Total 13F shares, excl. options
-
37.8M
-
Shares change
-
+1.68M
-
Total reported value, excl. options
-
$315M
-
Value change
-
+$15.5M
-
Number of buys
-
78
-
Number of sells
-
-48
-
Price
-
$8.33
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q2 2020
146 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q2 2020.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 133 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 37.8M shares
of 166M outstanding shares and own 22.81% of the company stock.
Largest 10 shareholders include BlackRock Inc. (4.14M shares), BVF INC/IL (3.12M shares), VANGUARD GROUP INC (2.65M shares), PERCEPTIVE ADVISORS LLC (2.58M shares), RENAISSANCE TECHNOLOGIES LLC (2.35M shares), VICTORY CAPITAL MANAGEMENT INC (2.28M shares), STATE STREET CORP (2.2M shares), RTW INVESTMENTS, LP (1.51M shares), GREAT POINT PARTNERS LLC (1.45M shares), and Point72 Asset Management, L.P. (1.03M shares).
This table shows the top 133 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.